What is Redx Pharma?
Founded in 2010 and headquartered in the United Kingdom, Redx Pharma is dedicated to enhancing existing drug classes to create new therapeutic agents. The company's research and development efforts are concentrated on addressing unmet needs in oncology, infectious diseases, and autoimmune disorders. By focusing on improving the characteristics of established drug families, Redx Pharma aims to de-risk the drug development process and bring innovative treatments to patients more efficiently. Their strategic approach targets areas with significant therapeutic potential and market demand.
How much funding has Redx Pharma raised?
Redx Pharma has raised a total of $15.2M across 2 funding rounds:
Private Equity
$14.2M
Grant
$1M
Private Equity (2016): $14.2M, investors not publicly disclosed
Grant (2017): $1M led by Carb-X
Key Investors in Redx Pharma
Carb-X
CARB-X is a global non-profit accelerator focused on combating dangerous drug-resistant bacteria by supporting the development of new antibiotics and other life-saving products. They invest in early-stage projects aimed at preventing, diagnosing, and treating bacterial infections.
What's next for Redx Pharma?
With the recent strategic investment and substantial overall capital, Redx Pharma is poised for an accelerated phase of growth and development. The company is likely to focus on advancing its lead drug candidates through clinical trials, expanding its research capabilities, and potentially forging new partnerships. This enterprise-level backing suggests confidence from investors in Redx Pharma's scientific platform and its potential to deliver impactful new medicines. The company's trajectory indicates a move towards scaling its operations and achieving key development milestones in the coming years.
See full Redx Pharma company page
